



1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

HJM
3/12/03

APPLICATION OF : Toshihiko Yanagita
FOR : DRUG FOR INHIBITING MYOMETRIAL
CONTRACTION
SERIAL NO. : 10/030,298
FILED : December 21, 2002
EXAMINER : Unknown
ART UNIT : MAR 14 2003 1642

RECEIVED

ATTORNEY DOCKET NO. TECH CENTER 1600/2900 YAMZ 2 00014

March 7, 2003
Cleveland, OH 44114-2579**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, 1.97, 1.98 and MPEP § 609, applicant submits the following Disclosure Statement concerning art of which the applicant is aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

CERTIFICATE OF MAILING

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT** is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on March 7, 2003.

By: Lyneta S. Kalemba
Lyneta S. Kalemba

Under § 1.98(a)(3), no concise explanation of relevance is required for information that is in the English language. Accordingly, the enclosed patent requires no further explanation (or no translation is available).

Consideration of the appropriate paragraph(s) indicated below is respectfully requested:

[] **WITHIN THREE MONTHS OF FILING:** Under § 1.97(b)(1), this information disclosure statement is being filed within three months of the filing date of the application. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.


[X] **BEFORE FIRST OFFICE ACTION:** Under § 1.97(b)(3), this information disclosure statement is being filed before the mailing date of a first Office Action on the merits. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

[X] **FOREIGN SEARCH REPORT:** Under § 1.97(e)(1), the undersigned certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

It is respectfully requested that the attached document(s) be considered and officially cited in examination of this application.

Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP



Richard M. Klein
Reg. No.33,000
1100 Superior Avenue, Seventh Floor
Cleveland, Ohio 44114-2518
(216) 861-5582



Subst. Form PTO-1449 APPLICANT(S)' INFORMATION DISCLOSURE STATEMENT		Atty.Dkt.No: YAMZ 2 00014	Serial No.: 10/030,298				
		Applicant(s): Toshihiko Yanagita					
		Filing Date: December 21, 2001		Group: 1642			
U.S. PATENT DOCUMENTS							
Initial * AA AB AC AD AE AF AG	Document No. 5,910,482	Date 08 JUN 1999	Name Yallampalli et al.	Class 514	Subcl. 12	Filing Date 19 MAR 1996	RECEIVED MAR 14 2003 TECH CENTER 1600/2900
FOREIGN PATENT DOCUMENTS							
	Document No. 0 622 458 A2	Date 02 NOV 1994	Country EPO	Class	Subcl.	Translation?	
AH							
AJ							
AK							
AL							
AM							
AN							
OTHER ART							
AO	MICHISHITA M., ET AL., "Expression of adrenomedullin in the endometrium of the human uterus." <i>Obstetrics & Gynecology</i> , vol. 93, no. 1, January 1999 (1999-01), pages 66-70						
AP	EGUCHI S., ET AL., "Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells," <i>Endocrinology</i> , Baltimore, MD, vol. 135, no. 6, 1994, pages 2454-2458						
Examiner:				Date Considered:			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.							